利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

54 条记录 (耗时 0.089 秒)

    Quinazoline derivatives and their use in the treatment of cancer
    31.
    发明授权
    Quinazoline derivatives and their use in the treatment of cancer 失效
    喹唑啉衍生物及其在治疗癌症中的应用

    公开(公告)号：US07659279B2

    公开(公告)日：2010-02-09

    申请号：US10555085

    申请日：2004-04-27

    申请人： Laurent Francois Andre Hennequin ,  Alleyn Plowright

    发明人： Laurent Francois Andre Hennequin ,  Alleyn Plowright

    IPC分类号： A61K31/517 ,  C07D239/88

    CPC分类号： C07D403/12 ,  C07D403/14

    摘要： The invention concerns quinazoline derivatives of the formula: (I); wherein X1, Q1, Z, R1, R2, Y, a and m are as defined in the description, which are erbB tyrosine kinase inhibitors, particularly EGFR tyrosine kinase inhibitors. Also claimed are processes for their preparation; pharmaceutical compositions containing them; and their use as therapeutic agents in the treatment of erbB tyrosine kinase mediated diseases such as cancer.

    摘要翻译： 本发明涉及式（I）的喹唑啉衍生物： 其中X1，Q1，Z，R1，R2，Y，a和m如描述中所定义，其是erbB酪氨酸激酶抑制剂，特别是EGFR酪氨酸激酶抑制剂。 还要求他们的准备过程; 含有它们的药物组合物; 以及它们在治疗erbB酪氨酸激酶介导的疾病如癌症中的用途。

    4-ANILINO QUINAZOLINE DERIVATIVES AS ANTIPROLIFERATIVE AGENTS
    35.
    发明申请
    4-ANILINO QUINAZOLINE DERIVATIVES AS ANTIPROLIFERATIVE AGENTS 审中-公开
    4-苯胺喹诺酮衍生物作为抗增生剂

    公开(公告)号：US20080269487A1

    公开(公告)日：2008-10-30

    申请号：US12147250

    申请日：2008-06-26

    申请人： Robert Hugh Bradbury ,  Laurent Francois Andre Hennequin ,  Jason Grant Kettle

    发明人： Robert Hugh Bradbury ,  Laurent Francois Andre Hennequin ,  Jason Grant Kettle

    IPC分类号： C07D401/02

    CPC分类号： C07D401/12 ,  C07D403/12

    摘要： The invention concerns quinazoline derivatives of Formula (I) wherein each of Q1, Z, R1 and Q2 have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours which are sensitive to inhibition of erbB receptor tyrosine kinases.

    摘要翻译： 本发明涉及式（I）的喹唑啉衍生物，其中Q 1，Z，R 1和Q 2 2中的每一个具有定义的任何含义 在说明中; 其制备方法，含有它们的药物组合物及其在制备用于预防或治疗对erbB受体酪氨酸激酶抑制敏感的肿瘤中的抗增殖剂的药物中的用途。

    Quinazoline Derivatives
    36.
    发明申请
    Quinazoline Derivatives 审中-公开
    喹唑啉衍生物

    公开(公告)号：US20080234263A1

    公开(公告)日：2008-09-25

    申请号：US10572303

    申请日：2004-09-13

    申请人： Laurent Francois Andre Hennequin ,  Christopher Thomas Halsall

    发明人： Laurent Francois Andre Hennequin ,  Christopher Thomas Halsall

    IPC分类号： A61K31/5377 ,  C07D403/08 ,  A61K31/517 ,  C07D413/08

    CPC分类号： C07D403/06 ,  C07D401/06 ,  C07D413/06 ,  C07D413/14 ,  C07D417/06

    摘要： The invention concerns quinazoline derivatives of Formula (I) wherein each of R1, R3, R20, X1, X2, Z, W, (a) and (q) have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of turnours which are sensitive to inhibition of erbB receptor tyrosine kinases, particularly EGFR tyrosine kinase.

    摘要翻译： 本发明涉及式（I）的喹唑啉衍生物，其中R 1，R 3，R 20，X 1， Z，W，（a）和（q）具有本说明书中定义的任何含义; 其制备方法，含有它们的药物组合物及其在制备用于预防或治疗对抑制erbB受体酪氨酸激酶，特别是EGFR酪氨酸激酶敏感的转导酶的抗增生剂中的用途。

    Quinazoline Derivatives As Angiogenesis Inhibitors
    37.
    发明申请
    Quinazoline Derivatives As Angiogenesis Inhibitors 失效
    喹唑啉衍生物作为血管生成抑制剂

    公开(公告)号：US20080058342A1

    公开(公告)日：2008-03-06

    申请号：US10566842

    申请日：2004-08-05

    申请人： Laurent Francois Andre Hennequin

    发明人： Laurent Francois Andre Hennequin

    IPC分类号： A61K31/517 ,  A61K31/496 ,  A61P35/00 ,  A61P9/00 ,  C07D401/14 ,  C07D403/14

    CPC分类号： C07D401/14 ,  C07D403/10 ,  C07D403/14

    摘要： The present invention relates to compounds of the Formula (I): wherein: ring C is an 8, 9, 10, 12 or 13-membered bicyclic or tricyclic moiety which moiety may be saturated or unsaturated, which may be aromatic or non-aromatic, and which optionally may contain 1-3 heteroatoms selected independently from O, N and S; is —O— —NH— or —S—; is 0, 1, 2, 3, 4 or 5; is 0, 1, 2 or 3; and R2 and R1 are as defined herein; and salts thereof; their use in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in warm blooded animals; processes for the preparation of such compounds; pharmaceutical compositions containing a compound of Formula (I) or a pharmaceutically acceptable salt thereof and methods of treating disease states involving angiogenesis by administering a compound of formula I or a pharmaceutically acceptable salt thereof. The compounds of Formula (I) inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis.

    摘要翻译： 本发明涉及式（I）的化合物：其中：环C是8,9,10,12或13元双环或三环部分，该部分可以是饱和或不饱和的，其可以是芳族或非芳族的 ，并且其任选地可以含有1-3个独立地选自O，N和S的杂原子; 是-O-NH-或-S-; 是0，1，2，3，4或5; 是0，1，2或3; 且R 2和R 1如本文所定义; 及其盐; 它们在制备用于在温血动物中产生抗血管生成和/或血管通透性降低作用的药物中的用途; 制备这些化合物的方法; 含有式（I）化合物或其药学上可接受的盐的药物组合物和通过给予式I化合物或其药学上可接受的盐治疗涉及血管发生的疾病状态的方法。 式（I）的化合物抑制VEGF的作用，其在治疗许多疾病状态（包括癌症和类风湿性关节炎）中是有价值的。

    Quinazoline compounds
    39.
    发明授权
    Quinazoline compounds 失效

    公开(公告)号：US07268230B2

    公开(公告)日：2007-09-11

    申请号：US10502538

    申请日：2003-01-28

    申请人： Laurent Francois Andre Hennequin

    发明人： Laurent Francois Andre Hennequin

    IPC分类号： C07D471/04 ,  C07D401/14 ,  C07D403/12 ,  A61K31/517

    CPC分类号： C07D401/14 ,  C07D403/12 ,  C07D471/04 ,  C07D491/04

    摘要： The invention relates to compounds of the formula (I): wherein ring C is as defined herein, for example indolyl, indazolyl or azaindolyl; Z is —O—, —NH— or —S—; n is 0-5; m is 0-3; R1 and R2 are defined herein including groups: (i) Q1X1 wherein Q1 and X1 are as defined herein; (ii) Q15W3 wherein Q15 and W3 are as defined herein, (iii) Q21W4C1-5alkylX1— wherein Q21, W4 and X1 are as defined herein, (iv) Q28C1-5alkylX1—, Q28C2-5alkenylX1— or Q28C2-5alkynylX1— wherein Q28 and X1 are as defined herein and (v) Q29C1-5alkylX1—, Q29C2-5alkenylX1— or Q29C2-5alkynylX1— wherein Q29 and X1 are as defined herein; R2 can also be 6,7-methylenedioxy or 6,7-ethylenedioxy; and salts thereof; their use in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in warm?blooded animals; processes for the preparation of such compounds; intermediates used in such processes; processes for making such intermediates; pharmaceutical compositions containing a compound of formula I or a pharmaceutically acceptable salt thereof and methods of treating disease states involving angiogenesis by administering a compound of formula I or a pharmaceutically acceptable salt thereof. The compounds of formula I inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis.

    3-Cyano-quinoline derivatives
    40.
    发明申请
    3-Cyano-quinoline derivatives 审中-公开
    3-氰基 - 喹啉衍生物

    公开(公告)号：US20070191346A1

    公开(公告)日：2007-08-16

    申请号：US11642978

    申请日：2006-12-21

    申请人： Laurent Francois Andre Hennequin

    发明人： Laurent Francois Andre Hennequin

    IPC分类号： A61K31/551 ,  A61K31/55 ,  A61K31/541 ,  A61K31/5377 ,  A61K31/496 ,  A61K31/4709 ,  C07D417/14 ,  C07D413/14 ,  C07D407/14

    CPC分类号： C07D405/12

    摘要： The invention concerns quinoline derivatives of Formula (I) wherein each of Z1, m, R1, n, R3, Z2 and R14 have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an anti-invasive or anti-proliferative agent in the containment and/or treatment of solid tumour disease.

    摘要翻译： 本发明涉及式（I）的喹啉衍生物，其中Z 1，m，R 1，n，R 3，Z， > 2 和R 14具有上文在描述中定义的任何含义; 其制备方法，含有它们的药物组合物及其在制备用于在实体瘤疾病的遏制和/或治疗中作为抗侵袭性或抗增殖剂的药物的用途。